CORRECTION: Myovant Sciences to Participate in Upcoming September Investor Conferences
August 27 2019 - 1:26PM
A correction has been issued for the release disseminated today at
8:30 AM ET. The date for Lynn Seely's presentation was incorrectly
listed. The complete and corrected release follows:
Myovant Sciences (NYSE: MYOV), a clinical-stage healthcare
company focused on developing and commercializing innovative
therapies for women’s health and prostate cancer, today announced
its participation in the following upcoming investor
conferences:
- Citi's 14th Annual Biotech Conference
in Boston, MA. Myovant will host meetings with investors at
the conference on Wednesday, September 4, 2019.
- Baird 2019 Global Healthcare Conference
in New York, NY. Lynn Seely, MD, Myovant's President and Chief
Executive Officer, will participate in a fireside chat on Thursday,
September 5, 2019, in a session scheduled to begin at 2:35 p.m. ET.
- BioCentury’s 26th Annual Newsmakers in the Biotech
Industry Conference in New York, NY. Lynn Seely, MD,
will present on Friday, September 6, 2019, in a session scheduled
to begin at 9:00 a.m. ET.
A live webcast of the Baird 2019 Global Healthcare Conference
will be accessible on the Events page under the Investors
& Media section of the Myovant website
at www.myovant.com. Please connect to the company's website at
least 15 minutes prior to the presentation to ensure adequate time
for any software download that may be required to listen to the
webcast. A replay of the webcast will be available at the same
location for 30 days following the conference.
About Myovant Sciences Myovant
Sciences aspires to be the leading healthcare company focused
on innovative treatments for women's health and prostate cancer.
Myovant Science’s lead product candidate is relugolix, an oral,
once-a-day small molecule that acts as a GnRH receptor antagonist.
Myovant Sciences has three late-stage clinical programs for
relugolix ongoing in uterine fibroids, endometriosis and prostate
cancer. Myovant Sciences is also developing MVT-602, an
oligopeptide kisspeptin-1 receptor agonist, that has completed a
Phase 2a study for the treatment of female infertility as part of
assisted reproduction. Takeda Pharmaceuticals International
AG granted Myovant Sciences an exclusive, worldwide license to
develop and commercialize relugolix (excluding Japan and
certain other Asian countries) and an exclusive license to develop
and commercialize MVT-602 in all countries worldwide. Over time,
Myovant intends to expand its development pipeline to include other
potential treatments for women's health and prostate cancer. For
more information, please visit Myovant Science's website
at www.myovant.com. Follow @Myovant on Twitter and LinkedIn
(https://www.linkedin.com/company/myovant-sciences).
Investor Contact: Frank Karbe Chief Financial
Officer Myovant Sciences, Inc.investors@myovant.com
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024